ArticleTranslational lung cancer research2025
Endocrine immune-related adverse events in advanced lung cancer patients receiving immune checkpoint inhibitors: incidence, predictors and outcomes.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical Outcomes and Immune-Related Adverse Events in Metastatic Non-Squamous NSCLC Treated with First-Line Pembrolizumab-Chemotherapy: A Real-World Study from Serbia.Current oncology (Toronto, Ont.) · 2026Article
- Development and internal validation of a prognostic nomogram for lung metastasis in locally advanced rectal cancer incorporating molecular markers.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitors (ICIs) have markedly improved outcomes in lung cancer but may lead to immune-related adverse events (irAEs). Among them, endocrine irAEs (e-irAEs) are frequent, yet their risk factors and prognostic implications remain unclear. This study aimed to investigate the incidence, predictors, and clinical outcomes of e-irAEs in patients with advanced lung cancer receiving ICIs. Methods: In this single-center retrospective cohort study, we analyzed patients with advanced lung cancer who received at least 2 cycles of ICIs from January 2019 to October 2023 at West China Hospital of Sichuan University. Patients were categorized into e-irAE and no e-irAE groups. The cumulative incidence of e-irAE was estimated using the Aalen-Johansen method, accounting for death as a competing risk. Risk factors for e-irAEs were assessed using Fine-Gray subdistribution hazard model and logistic regression, while a time-dependent Cox model was employed to evaluate the impact of e-irAEs on progression-free survival (PFS) and overall survival (OS). Results: Our analysis included 603 patients in total, 60 (10.0%) developed e-irAEs, predominantly hypothyroidism (73.3%) and thyrotoxicosis (23.3%), with a median onset of 4.0 months. During follow-up, 261 (43.3%) patients died. Female sex [subdistribution hazard ratio (SHR), 2.27; 95% confidence interval (CI), 1.23-4.21; P=0.009], lung metastasis (SHR, 1.79; 95% CI, 1.07-3.02; P=0.03), elevated thyroid stimulating hormone (TSH) (SHR, 1.04; 95% CI, 1.02-1.06; P<0.001), increased eosinophil count (SHR, 1.66; 95% CI, 1.32-2.10; P<0.001), and objective response (SHR, 2.23; 95% CI, 1.25-3.97; P=0.007) were associated with higher risk of e-irAE development. Patients with e-irAEs had superior OS (median 42.0 Conclusions: e-irAEs occurred in approximately 10% of advanced lung cancer patients receiving ICIs. Predictors of e-irAE development included female sex, lung metastasis, increased eosinophil count, elevated TSH, and objective response to ICIs. Patients with e-irAE occurrence tended to have a favorable survival outcome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.